Bayer Aktiengesellschaft (BAYRY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sy ...

Criteo S.A. (CRTO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors ...

Kingfisher PLC (KGFHY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the syst ...

Adidas AG (ADDYY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system ...

Group 1 - Origin Bancorp (OBK) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which significantly impacts stock prices [1][3] - The Zacks rating system focuses on changes in earnings estimates, providing a more objective measure for investors compared to traditional Wall Street ratings [2][6] - The upgrade reflects a positive outlook on Origin Bancorp's earnings, potentially leading to increased buying pressure and a rise in stock price [3][5] Group 2 - The correlation between earnings estimate revisions and stock price movements is strong, with institutional investors using these estimates to determine fair value [4][6] - Rising earnings estimates indicate an improvement in the company's underlying business, suggesting that investors may respond positively by driving the stock price higher [5][10] - The Zacks Rank system classifies stocks based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating superior potential for market-beating returns [9][10] Group 3 - For the fiscal year ending December 2025, Origin Bancorp is expected to earn $3.18 per share, with a 1.4% increase in the Zacks Consensus Estimate over the past three months [8]

Silvercorp (SVM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earni ...

Core Viewpoint - Nurix Therapeutics, Inc. (NRIX) has seen a 2.3% increase in share price over the past four weeks, closing at $12.44, with analysts suggesting a potential upside of 143.4% based on a mean price target of $30.28 [1] Price Targets - The average of 18 short-term price targets ranges from a low of $16.00 to a high of $41.00, with a standard deviation of $6.49, indicating variability among estimates [2] - The lowest estimate suggests a 28.6% increase from the current price, while the highest estimate indicates a 229.6% upside [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about NRIX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.7%, with two estimates moving higher and no negative revisions [12] Zacks Rank - NRIX currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Scorpio Tankers (STNG) closed the last trading session at $41.85, gaining 4.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $62.71 indicates a 49.8% upside potential.The average comprises seven short-term price targets ranging from a low of $42.00 to a high of $75.00, with a standard deviation of $11.93. While the lowest estimate indicates an increase of 0.4% from the current pr ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Gray Media (GTN) .Gray Media currently has an average brokerage r ...

Core Viewpoint - Johnson & Johnson is currently under observation due to its stock performance and potential future direction, particularly in relation to earnings estimates and revenue growth [1][2]. Earnings Estimate Revisions - For the current quarter, Johnson & Johnson is expected to report earnings of $2.64 per share, reflecting a decrease of -6.4% year-over-year, with a slight increase of +0.5% in the Zacks Consensus Estimate over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $10.62, indicating a growth of +6.4% from the previous year, with a minor adjustment of +0.1% in the last month [5]. - For the next fiscal year, the earnings estimate stands at $11, suggesting a growth of +3.6% compared to the prior year, with a recent increase of +0.2% [6]. - Johnson & Johnson holds a Zacks Rank 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $22.77 billion, representing a year-over-year increase of +1.4% [11]. - For the current fiscal year, the revenue estimates are $91.19 billion and $94.24 billion, indicating growth rates of +2.7% and +3.4%, respectively [11]. Last Reported Results and Surprise History - In the last reported quarter, Johnson & Johnson achieved revenues of $21.89 billion, a year-over-year increase of +2.4%, and an EPS of $2.77, up from $2.71 a year ago [12]. - The company exceeded the Zacks Consensus Estimate for revenues by +1.26% and for EPS by +7.78% [12]. - Johnson & Johnson has consistently beaten consensus EPS and revenue estimates over the past four quarters [13]. Valuation - Johnson & Johnson is graded B in the Zacks Value Style Score, indicating it is trading at a discount compared to its peers [17].